Literature DB >> 22687578

Seroepidemiology of mumps in Europe (1996-2008): why do outbreaks occur in highly vaccinated populations?

J Eriksen1, I Davidkin2, G Kafatos3, N Andrews3, C Barbara4, D Cohen5, A Duks6, A Griskevicius7, K Johansen8, K Bartha9, B Kriz10, G Mitis11, J Mossong12, A Nardone3, D O'Flanagan13, F DE Ory14, A Pistol15, H Theeten16, K Prosenc17, M Slacikova18, R Pebody3.   

Abstract

Mumps outbreaks have recently been recorded in a number of highly vaccinated populations. We related seroprevalence, epidemiological and vaccination data from 18 European countries participating in The European Sero-Epidemiology Network (ESEN) to their risk of mumps outbreaks in order to inform vaccination strategies. Samples from national population serum banks were collected, tested for mumps IgG antibodies and standardized for international comparisons. A comparative analysis between countries was undertaken using age-specific mumps seroprevalence data and information on reported mumps incidence, vaccine strains, vaccination programmes and vaccine coverage 5-12 years after sera collection. Mean geometric mumps antibody titres were lower in mumps outbreak countries [odds ratio (OR) 0·09, 95% confidence interval (CI) 0·01-0·71)]. MMR1 vaccine coverage ⩾95% remained protective in a multivariable model (P < 0·001), as did an interval of 4-8 years between doses (OR 0·08, 95% CI 0·01-0·85). Preventing outbreaks and controlling mumps probably requires several elements, including high-coverage vaccination programmes with MMR vaccine with 4-8 years between doses.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22687578      PMCID: PMC9152080          DOI: 10.1017/S0950268812001136

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   4.434


  48 in total

Review 1.  MMR vaccination and disease elimination: the Finnish experience.

Authors:  Irja Davidkin; Mia Kontio; Mikko Paunio; Heikki Peltola
Journal:  Expert Rev Vaccines       Date:  2010-09       Impact factor: 5.217

2.  Model selection methodology for inter-laboratory standardisation of antibody titres.

Authors:  George Kafatos; Nick Andrews; Anthony Nardone
Journal:  Vaccine       Date:  2005-10-10       Impact factor: 3.641

3.  Interpreting serological surveys using mixture models: the seroepidemiology of measles, mumps and rubella in England and Wales at the beginning of the 21st century.

Authors:  A J Vyse; N J Gay; L M Hesketh; R Pebody; P Morgan-Capner; E Miller
Journal:  Epidemiol Infect       Date:  2006-05-02       Impact factor: 2.451

4.  Mumps outbreak among the military in Luxembourg in 2008: epidemiology and evaluation of control measures.

Authors:  J Mossong; C Bonert; P Weicherding; M Opp; P Reichert; J Even; F Schneider
Journal:  Euro Surveill       Date:  2009-02-19

5.  Mumps outbreaks in vaccinated populations: are available mumps vaccines effective enough to prevent outbreaks?

Authors:  Gustavo H Dayan; Steven Rubin
Journal:  Clin Infect Dis       Date:  2008-12-01       Impact factor: 9.079

6.  Sero-epidemiology of mumps in western Europe.

Authors:  A Nardone; R G Pebody; S van den Hof; D Levy-Bruhl; A M Plesner; M C Rota; A Tischer; N Andrews; G Berbers; P Crovari; W J Edmunds; G Gabutti; P Saliou; E Miller
Journal:  Epidemiol Infect       Date:  2003-08       Impact factor: 2.451

Review 7.  Increased mumps incidence in the Netherlands: review on the possible role of vaccine strain and genotype.

Authors:  P Kaaijk; Ba van der Zeijst; Mc Boog; Cw Hoitink
Journal:  Euro Surveill       Date:  2008-06-26

Review 8.  The virtual elimination of rubella and mumps from the United States and the use of combined measles, mumps and rubella vaccines (MMR) to eliminate measles.

Authors:  K J Bart; W A Orenstein; A R Hinman
Journal:  Dev Biol Stand       Date:  1986

9.  Comparison of rubella seroepidemiology in 17 countries: progress towards international disease control targets.

Authors:  Anthony Nardone; Annedore Tischer; Nick Andrews; Jo Backhouse; Heidi Theeten; Nina Gatcheva; Marios Zarvou; Bohumir Kriz; Richard G Pebody; Kalman Bartha; Darina O'Flanagan; Dani Cohen; Arnis Duks; Algirdas Griskevicius; Joel Mossong; Christopher Barbara; Adrianna Pistol; Margareta Slaciková; Katarina Prosenc; Kari Johansen; Elizabeth Miller
Journal:  Bull World Health Organ       Date:  2008-02       Impact factor: 9.408

10.  Persistence of mumps antibodies after 2 doses of measles-mumps-rubella vaccine.

Authors:  Charles W LeBaron; Bagher Forghani; Carol Beck; Cedric Brown; Daoling Bi; Cynthia Cossen; Bradley J Sullivan
Journal:  J Infect Dis       Date:  2009-02-15       Impact factor: 5.226

View more
  29 in total

1.  Characteristics of a large mumps outbreak: Clinical severity, complications and association with vaccination status of mumps outbreak cases.

Authors:  C Stein Zamir; H Schroeder; H Shoob; N Abramson; G Zentner
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Estimates of mumps seroprevalence may be influenced by antibody specificity and serologic method.

Authors:  Donald R Latner; Marcia McGrew; Nobia J Williams; Sun B Sowers; William J Bellini; Carole J Hickman
Journal:  Clin Vaccine Immunol       Date:  2013-12-26

3.  Challenges in Interpretation of Diagnostic Test Results in a Mumps Outbreak in a Highly Vaccinated Population.

Authors:  L A Trotz-Williams; N J Mercer; K Paphitis; J M Walters; D Wallace; E Kristjanson; J Gubbay; T Mazzulli
Journal:  Clin Vaccine Immunol       Date:  2017-02-06

4.  Environmental factors potentially associated with mumps transmission in yeshivas during a mumps outbreak among highly vaccinated students: Brooklyn, New York, 2009-2010.

Authors:  Amy Parker Fiebelkorn; Jennifer B Rosen; Cedric Brown; Christopher M Zimmerman; Hyman Renshowitz; Christopher D'Andrea; Kathleen M Gallagher; Rafael Harpaz; Jane R Zucker
Journal:  Hum Vaccin Immunother       Date:  2013-01       Impact factor: 3.452

5.  Epidemiology and the economic assessment of a mumps outbreak in a highly vaccinated population, Orange County, New York, 2009-2010.

Authors:  Preeta Krishnan Kutty; Jacqueline Lawler; Elizabeth Rausch-Phung; Ismael R Ortega-Sanchez; Stephen Goodell; Cynthia Schulte; Lynn Pollock; Barbara Valure; Jean Hudson; Kathleen Gallagher; Debra Blog
Journal:  Hum Vaccin Immunother       Date:  2014-03-14       Impact factor: 3.452

6.  Serological survey of mumps antibodies in adults in the Czech Republic and the need for changes to the vaccination strategy.

Authors:  Jan Smetana; Roman Chlibek; Irena Hanovcova; Renata Sosovickova; Libuse Smetanova; Petra Polcarova; Peter Gal; Petr Dite
Journal:  Hum Vaccin Immunother       Date:  2018-01-16       Impact factor: 3.452

7.  Pre-vaccination IgG screening for mumps is the most cost-effectiveness immunization strategy among Health Care Workers.

Authors:  Luca Coppeta; Ottavia Balbi; Savino Baldi; Antonio Pietroiusti; Andrea Magrini
Journal:  Hum Vaccin Immunother       Date:  2019-03-27       Impact factor: 3.452

8.  Seroprevalence of antibodies against measles, rubella, mumps, varicella-zoster, and B. Pertussis in young adults of Madrid, Spain.

Authors:  Alba González-Escalada; Laura García-García; Pablo Viguera-Ester; Patricia Marín-García; Jesus García; Angel Gil-de-Miguel; Ruth Gil-Prieto
Journal:  Hum Vaccin Immunother       Date:  2013-06-21       Impact factor: 3.452

9.  Outbreak-related mumps vaccine effectiveness among a cohort of children and of young adults in Germany 2011.

Authors:  Anja Takla; Merle M Böhmer; Christina Klinc; Norbert Kurz; Alice Schaffer; Heribert Stich; Petra Stöcker; Ole Wichmann; Judith Koch
Journal:  Hum Vaccin Immunother       Date:  2013-10-07       Impact factor: 3.452

10.  Viral etiology of mumps-like illnesses in suspected mumps cases reported in Catalonia, Spain.

Authors:  Irene Barrabeig; Josep Costa; Ariadna Rovira; M Angeles Marcos; Ricard Isanta; Rubén López-Adalid; Ana Cervilla; Nuria Torner; Angela Domínguez
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.